NBIX:NASDAQ
Neurocrine Biosciences, Inc
$148.66
arrow_downward
-2.09%(-3.17) 1D
Sep 18, 1:42:31 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$152.63
High
$152.63
Low
$147.76
Mkt. cap
15.11B
Avg. vol.
1.11M
Volume
549.63K
P/E ratio
21.79
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.38
Shares outstanding
101.65M
No. of employees
2K
Open
$152.63
High
$152.63
Low
$147.76
Mkt. cap
15.11B
Avg. vol.
1.11M
Volume
549.63K
P/E ratio
21.79
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.38
Shares outstanding
101.65M
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
13 hours ago
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
Kalkine Media
·
2 days ago
Neurocrine Biosciences CEO Gano Kyle Receives 8,117 Shares at No Cost, Forfeits 4,380 Shares on September 11, 2026
https://www.dars.gov.et/
·
1 month ago
NBIX Q1 2026 Earnings: Strong EPS Beat Drives Positive Market Response - Earnings Outlook Update
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com